Literature DB >> 12072085

Lymphocytic infiltrates as a presenting feature of Sweet's syndrome with myelodysplasia and response to cyclophosphamide.

A V Evans1, R A Sabroe, K Liddell, R Russell-Jones.   

Abstract

Sweet's syndrome has a well-recognized association with malignancies, around half of which have been acute myelogenous leukaemia. There are also numerous reports of Sweet's syndrome in association with myelodysplasia. We report two patients with Sweet's syndrome in whom the classical histological appearances were preceded by dermal lymphocytic infiltrates. A literature search using PubMed indicates that this phenomenon has not been previously reported. The cases demonstrate the chronicity of Sweet's lesions in association with haematological disease and the need for repeat biopsies to make the diagnosis. We also describe successful treatment with cyclophosphamide, which adds to the list of second-line drugs that may be used in Sweet's syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072085     DOI: 10.1046/j.1365-2133.2002.04701.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients.

Authors:  Lisa Ghoufi; Nicolas Ortonne; Saskia Ingen-Housz-Oro; Walid Barhoumi; Edouard Begon; Corinne Haioun; Cécile Pautas; Florence Beckerich; Christine Robin; Pierre Wolkenstein; Catherine Cordonnier; Olivier Chosidow; Andréa Toma
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

2.  Atypical Histiocyte-Rich Sweet's Syndrome.

Authors:  Sharon Chi; Marcia Leung; Mark Carmichael; Michael Royer; Sunghun Cho
Journal:  Case Rep Dermatol Med       Date:  2017-10-18

Review 3.  Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Authors:  Philip R Cohen
Journal:  Orphanet J Rare Dis       Date:  2007-07-26       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.